The deal comes as the firms try — for the second time — to close a merger that had previously failed to gain necessary approval from Rosetta shareholders.
The Fondazione Luigi Maria Monti - Istituto Dermopatico dell' Immacolata research hospital in Rome will perform SelectMDx testing locally.
The test is based on the company's GARD platform for measuring genetic biomarkers of immune reactions to predict chemical sensitivities.
The company offers a range of tumor profiling products including the OncoDeep solid tumor test and the OncoTrace liquid biopsy test.
Launch Diagnostics will distribute BioGx's entire product line, including laboratory-use-only products, in the UK and Ireland.
AxonLab will distribute BioGx's entire product line, including laboratory-use-only products, in central European countries.
The company has signed four distribution agreements for its products, covering six European nations.
AmoyDx's molecular diagnostics tests, powered by its ADx-ARMS and Super-ARMS technologies, will be made available in Hong Kong and Macau.
Genext will market and distribute OncoDNA's line of tumor profiling products and services including its liquid biopsy tests.
The deal covers IncellDx's portfolio of immune-oncology and oncology diagnostic products including its single-cell assay for quantifying PD-L1 on tumor cells and immune cell subtypes.
Berkeley researchers have engineered yeast to make the molecule behind the hoppy taste of beer, Quartz reports.
King's College London researchers examine the influence of school type and genetics on academic achievement.
FiveThirtyEight writes that most who take a direct-to-consumer BRCA1/2 genetic test won't learn much from it.
In Science this week: early life experience influence somatic variation in the genome, and more.